Role of beta blockers following percutaneous coronary intervention for acute coronary syndrome.
Kah Yong Peck, Nick Andrianopoulos, Diem Dinh, Louise Roberts, Stephen J Duffy, Martin Sebastian, David Clark, Angela Brennan, Ernesto Oqueli, Andrew E Ajani, Christopher M Reid, Melanie Freeman, Andrew W Teh
Heart | Published : 2021
AIMS: There is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The aim of this study was to evaluate BB use post PCI and its association with mortality. Furthermore, the study aimed to evaluate the association between BB and mortality in the subgroups of patients with left ventricular ejection fraction (LVEF) 50%. METHODS: Using a large PCI registry, data from patients with ACS between January 2005 and June 2017 who were alive at 30 days were analysed. Those patients taking BB at 30 days were compared with those who were not taking BB. The primary outcome was all-cause mortality...View full abstract